Bioheart, Inc. Announces Clinical Trials In India

SUNRISE, FL--(Marketwired - July 07, 2014) - Bioheart, Inc. (OTCQB: BHRT) announced today that they have begun two clinical trials in India including the first ever combination stem cell trial in the world. The first cardiac patient has successfully been enrolled and treated in India using AdipoCell™ or adipose derived stem cells. The second trial will involve the combination of AdipoCell and MyoCell® or muscle derived stem cells for congestive heart failure patients. AdipoCell may help to promote angiogenesis or new blood vessel formation in ischemic tissue while MyoCell may help to promote myogenesis or new muscle formation.

Himanshu Bansal, MD, the study manager, said, "With India's population and growing middle class the opportunities with Bioheart are limitless and we have many patients in India who can benefit from regenerative medicine and the Bioheart products. Conducting the first ever combination stem cell trial in the world will provide insights into future treatments."

The trials are fully funded by Bioheart and Revita Lifesciences (http://www.revitalife.co.in/). The first patient has been treated in India at the Yatharth Hospital at Noida (http://www.yatharthwellness.com/). This study will complement the data completed in the ANGEL trial on patients with congestive heart failure (CHF). All patients will receive delivery into the damaged areas of the heart using the MyoCath® Catheter. Data endpoints will include safety, exercise capacity, quality of life, and ejection fraction at 3 months and 6 months.

"Every week Bioheart is receiving interest from around the globe and conducting trials in India is another example of our team answering that call," said Kristin Comella, Bioheart's Chief Science Officer. "Bioheart therapies are now being utilized in over a dozen countries around the globe."

About Bioheart, Inc.

Bioheart, Inc. is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

About Revita Lifesciences

Revita Life Sciences is a biotechnology company which provides complete support to patients from query to till patient gets right stem cell therapy from our specialized doctors on board. Our primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need. Many years of research and experience have resulted in substantial improvements in the health and condition of patients with various diseases, even where other treatments have failed.

With the highest quality therapies, specialized doctors' team at Revita Life Sciences uses polyclonal, fresh, biologically intact stem cells directly from the patient (autologous adult stem cells) in order to improve their health. The patient's medical condition creates the appropriate environment in the body, resulting in a personalized therapy created especially for him.

Revita Life Sciences is carrying out research, training and clinical applications-protocol development in regenerative medicine, with emphasis on autologous adult Stem & Progenitor cells with regenerative capability to take them to clinical application, while maintaining the highest ethical and scientific values of international standards.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2013, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.